<< Back To Search

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
Scientists are studying a new treatment called iberdomide to see if it can help people with a type of blood cancer called smoldering multiple myeloma. They want to know if iberdomide, which helps the immune system fight cancer cells, can slow down the growth of the cancer. They will also be giving some patients a steroid called dexamethasone to see if it helps the iberdomide work better. The goal is to help people with this type of blood cancer stay healthier and give them more time before they start experiencing symptoms.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?